ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.599,57
-0,46%
S&P 500
5.222,68
0,16%
US Dollar vs BRL
5,1586
0,24%
Bitcoin
62.790,22
2,18%
Brent Oil
82,855
0,57%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Axogen Inc (AXGN)

  7. Axogen Inc (AXGN) Notícias

AXGN

Axogen (AXGN)

Axogen Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:AXGN
DataHoraFonteTítuloCódigoCompanhia
02/05/202408:00GlobeNewswire Inc.Axogen, Inc Reports First Quarter 2024 Financial ResultsNASDAQ:AXGNAxogen Inc
29/04/202417:50GlobeNewswire Inc.Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™NASDAQ:AXGNAxogen Inc
16/04/202408:00GlobeNewswire Inc.Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024NASDAQ:AXGNAxogen Inc
08/03/202419:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AXGNAxogen Inc
08/03/202418:38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AXGNAxogen Inc
07/03/202420:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AXGNAxogen Inc
06/03/202410:59Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AXGNAxogen Inc
06/03/202410:53Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:AXGNAxogen Inc
06/03/202410:45Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:AXGNAxogen Inc
05/03/202409:00GlobeNewswire Inc.Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial ResultsNASDAQ:AXGNAxogen Inc
14/02/202417:22Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AXGNAxogen Inc
13/02/202418:30GlobeNewswire Inc.Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024NASDAQ:AXGNAxogen Inc
12/02/202415:21Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:AXGNAxogen Inc
02/02/202418:15GlobeNewswire Inc.Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)NASDAQ:AXGNAxogen Inc
18/01/202419:00GlobeNewswire Inc.Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve CapNASDAQ:AXGNAxogen Inc
11/01/202419:10Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AXGNAxogen Inc
05/01/202419:21Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:AXGNAxogen Inc
04/01/202418:45GlobeNewswire Inc.Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023NASDAQ:AXGNAxogen Inc
04/01/202418:40GlobeNewswire Inc.Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025NASDAQ:AXGNAxogen Inc
04/01/202418:35GlobeNewswire Inc.Axogen Announces Promotions on Research and Development TeamNASDAQ:AXGNAxogen Inc
26/12/202318:15GlobeNewswire Inc.Axogen, Inc. Appoints Kathy Weiler to its Board of DirectorsNASDAQ:AXGNAxogen Inc
06/12/202309:00GlobeNewswire Inc.Axogen Announces Transition of Finance Team LeadershipNASDAQ:AXGNAxogen Inc
01/12/202319:00GlobeNewswire Inc.Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:AXGNAxogen Inc
20/11/202309:00GlobeNewswire Inc.Axogen, Inc. to Participate at the Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:AXGNAxogen Inc
07/11/202318:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AXGNAxogen Inc
07/11/202309:00GlobeNewswire Inc.Axogen, Inc. Reports 2023 Third Quarter Financial ResultsNASDAQ:AXGNAxogen Inc
18/10/202308:00GlobeNewswire Inc.Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023NASDAQ:AXGNAxogen Inc
05/09/202308:00GlobeNewswire Inc.Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector™NASDAQ:AXGNAxogen Inc
31/08/202308:00GlobeNewswire Inc.Axogen to Participate at Upcoming Investor ConferencesNASDAQ:AXGNAxogen Inc
21/08/202308:00GlobeNewswire Inc.Axogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, OhioNASDAQ:AXGNAxogen Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:AXGN

Seu Histórico Recente

EU
ASML
ASML Holding NV
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados